+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P07595(SIRT2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

SIRT2 antibodies are essential tools for studying the NAD+-dependent deacetylase sirtuin 2 (SIRT2), a member of the sirtuin family implicated in diverse cellular processes. SIRT2 primarily localizes to the cytoplasm but can shuttle to the nucleus, where it regulates critical pathways such as cell cycle progression, metabolic homeostasis, aging, and stress responses. It targets substrates including histone H3. α-tubulin, and PARP1. modulating their activity through deacetylation. Research links SIRT2 to neurodegenerative diseases (e.g., Parkinson’s and Alzheimer’s), cancer (acting as both tumor promoter and suppressor depending on context), and metabolic disorders, making it a therapeutic target of interest.

SIRT2 antibodies enable detection, quantification, and localization of the protein in various experimental setups, such as Western blotting, immunofluorescence, and immunoprecipitation. Their specificity is crucial, as isoforms or post-translational modifications may cross-react. Commercial antibodies are often raised against epitopes in the N-terminal catalytic domain or C-terminal region, with validation via knockout controls. Challenges include variability in reported expression levels across studies, partly due to antibody performance or tissue-specific SIRT2 isoforms. Recent studies also explore SIRT2 inhibitors/activators, driving demand for reliable antibodies to assess target engagement. Understanding SIRT2's dual roles in health and disease continues to rely on high-quality antibodies, underscoring their importance in both basic and translational research.